Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models [Yahoo! Finance]
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $177.00 to $175.00. They now have an "overweight" rating on the stock.
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health [Yahoo! Finance]
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
Sarepta Elevidys accelerated approval criticized by ICER exec [Seeking Alpha]